Randomised, Double-Blind, Cross-Over Study to Determine the 24-Hour FEV1-Time Profile of Orally Inhaled BI 1744 CL, Delivered With the Respimat Inhaler, After 3 Weeks of Once Daily or Twice Daily Administration in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

Randomised, Double-Blind, Cross-Over Study to Determine the 24-Hour FEV1-Time Profile of Orally Inhaled BI 1744 CL, Delivered With the Respimat Inhaler, After 3 Weeks of Once Daily or Twice Daily Administration in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2015

At a glance

  • Drugs Olodaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
    • 18 Apr 2012 Planned number of patients changed from 44 to 48 as reported by European Clinical Trials Database record.
    • 07 Aug 2009 Actual number of patients (47) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top